Calcium antagonists in heart failure

Area of Science:

• Cardiology
• Pharmacology

Background:

• Ischemic heart disease frequently causes congestive heart failure (CHF), leading to further left ventricular dysfunction.
• Calcium channel blockers (CCBs) may benefit patients with CHF and myocardial ischemia due to improved systolic function from decreased afterload.
• Concerns exist regarding CCBs' negative inotropic effects at high doses, potentially worsening systolic function.

Purpose of the Study:

• To establish the therapeutic role of CCBs in patients with CHF.
• To evaluate the hemodynamic effects of nifedipine in CHF patients.
• To assess the efficacy of nisoldipine in severe CHF.

Main Methods:

• Review of clinical data on oral/sublingual nifedipine administration in CHF.
• Analysis of hemodynamic changes including systemic vascular resistance, cardiac output, heart rate, and pressures.
• Evaluation of nisoldipine in a chronic 8-week study in severe CHF patients.

Main Results:

• Nifedipine administration decreased systemic vascular resistance by 33% and increased cardiac output by 24% in CHF patients.
• Heart rate remained largely unchanged, with minimal changes in right atrial pressures.
• Pulmonary capillary wedge pressure decreased by 16%, with a more favorable response in more severe CHF.
• Nisoldipine was evaluated in severe CHF over 8 weeks.

Conclusions:

• Nifedipine's dominant hemodynamic effect in CHF is vasodilation, reducing left ventricular afterload and improving cardiac output.
• The vasodilatory effect of nifedipine appears to outweigh potential negative inotropic effects in CHF patients.
• Further evaluation of CCBs like nisoldipine is warranted for severe CHF management.